VISIOGEN
Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions. The device is designed to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
VISIOGEN
Social Links:
Industry:
Health Care Medical Device
Founded:
2001-01-01
Address:
Irvine, California, United States
Country:
United States
Website Url:
http://www.visiogen.com
Total Employee:
11+
Status:
Closed
Contact:
949-341-0700
Total Funding:
85.5 M USD
Technology used in webpage:
SPF Amazon Amazon Virginia Region
Similar Organizations
InVivo Therapeutics
InVivo Therapeutics is a medical device company focused on developing restoration treatments for patients with spinal cord-injuries.
NinePoint Medical
NinePoint Medical is a transformational medical device company developing innovative, real-time, in vivo pathology devices.
Olympic Ophthalmics
Olympic Ophthalmics is a medical device company developing novel treatments for dry eye disease.
Current Advisors List
Founder
Investors List
Three Arch Partners
Three Arch Partners investment in Series D - Visiogen
CMEA Capital
CMEA Capital investment in Series D - Visiogen
New Leaf Venture Partners
New Leaf Venture Partners investment in Series D - Visiogen
Prospect Venture Partners
Prospect Venture Partners investment in Series D - Visiogen
Novartis Venture Fund
Novartis Venture Fund investment in Series D - Visiogen
Foundation Medical Partners
Foundation Medical Partners investment in Series D - Visiogen
Technology Partners
Technology Partners investment in Series D - Visiogen
New Leaf Venture Partners
New Leaf Venture Partners investment in Venture Round - Visiogen
CMEA Ventures
CMEA Ventures investment in Venture Round - Visiogen
Three Arch Partners
Three Arch Partners investment in Venture Round - Visiogen
Official Site Inspections
http://www.visiogen.com
- Host name: ec2-13-223-25-84.compute-1.amazonaws.com
- IP address: 13.223.25.84
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Visiogen"
Visiogen - Crunchbase Company Profile & Funding
Visiogen is an ophthalmic medical device company developing vision alternatives for patients with cataracts, with and without presbyopia. View contacts for Visiogen to access new leads and connect with decision-makers.See details»
ZEISS VisioGen
Start enhancing patient communication and streamline your clinic operations with ZEISS VisioGen, a cutting-edge AI-driven software designed to support you and your staff with fast and high-quality responses to patient inquiries.See details»
Visiogen, Inc. - LinkedIn
Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. The company plans to...See details»
Visiogen Company Profile 2024: Valuation, Investors, Acquisition ...
Developer of products for cataract and refractive patients. The company offers an accommodating intraocular lens, which provides distance, intermediate, and near vision to presbyopic cataract patients. Want detailed data on 3M+ companies? Want to dig into this profile? We’ll help you find what you need. 8. Merger/Acquisition. 7.See details»
Visiogen, Inc. Company Profile | Santa Ana, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Visiogen, Inc. of Santa Ana, CA. Get the latest business insights from Dun & Bradstreet.See details»
ZEISS expands ophthalmic offerings to improve patient care
Oct 9, 2024 · ZEISS VisioGen leverages generative AI (GenAI) for effective and efficient patient acquisition-as-a-service. The software solution provides digital communication services to offer fast, high-quality responses to patients.See details»
ZEISS expands ophthalmic offerings to improve patient care with …
Oct 11, 2024 · Extending the ZEISS digital portfolio, the company will introduce ZEISS VisioGen, a cutting-edge AI-driven solution designed to enhance refractive patient communication and streamline clinic operations, expanding the value to ophthalmologists and clinics by helping them grow their business through improved patient engagement. ZEISS VisioGen ...See details»
Visiogen joins Abbott portfolio - Ophthalmology Times
Oct 1, 2009 · Abbott expands its vision-care portfolio with the announcement of a definitive agreement to acquire Visiogen Inc., maker of a dual-optic accommodating lens (Synchrony).See details»
Visiogen - Funding, Financials, Valuation & Investors - Crunchbase
Visiogen is an ophthalmic medical device company developing vision alternatives for patients with cataracts, with and without presbyopia.See details»
VISIOGEN, INC. Company Profile | Milpitas, CA - Dun & Bradstreet
VISIOGEN, INC. Company Profile | Milpitas, CA | Competitors, Financials & Contacts - Dun & Bradstreet Find company research, competitor information, contact details & financial data for !company_name! of !company_city_state!. Get the latest business insights from Dun & Bradstreet.See details»
Visiogen - Products, Competitors, Financials, Employees, …
Visiogen is focused on developing products for cataract and refractive patients. Founded in Irvine, California, in 2001, Visiogen's first commercial application, Synchrony, a dual-optic intraocular lens and pre-loaded injector, is currently in clinical studies in the U.S. and recently received a CE Mark in Europe. Loading...See details»
Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
Sep 3, 2009 · Abbott (NYSE: ABT) has announced a definitive agreement to acquire Visiogen, Inc. for $400 million in cash, providing the company with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.See details»
Abbott completes acquisition of Visiogen - Ophthalmology Times
Nov 4, 2009 · Abbott Laboratories has completed its acquisition of privately held eye-care company Visiogen, adding to its vision-care business an accommodating IOL technology (Synchrony) designed to address presbyopia in patients with cataracts.See details»
Visiogen - Contacts, Employees, Board Members, Advisors & Alumni
Visiogen is an ophthalmic medical device company developing vision alternatives for patients with cataracts, with and without presbyopia.See details»
ABBOTT LABOR : Abbott to Acquire Visiogen, Expanding Vision …
Sep 2, 2009 · Visiogen, a privately held company based in Irvine, Calif., with European operations in Karlsruhe, Germany, is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts.See details»
ZEISS expands ophthalmic offerings to improve patient care
Oct 9, 2024 · ZEISS VisioGen leverages generative AI (GenAI) for effective and efficient patient acquisition-as-a-service. The software solution provides digital communication services to offer fast,...See details»
Abbott to buy Visiogen for $400 million - Ophthalmology Times
Sep 3, 2009 · Abbott announced a definitive agreement to acquire Visiogen Inc. for $400 million, providing the company with a next-generation accommodating IOL technology to address presbyopia for patients with cataracts.See details»
Visiogen - Crunchbase
Visiogen is an ophthalmic medical device company developing vision alternatives for patients with cataracts, with and without presbyopia.See details»
Abbott Laboratories Completes Visiogen, Inc. Acquisition
Oct 21, 2009 · Visiogen’s Synchrony(R) accommodating IOL is a significant advancement in artificial lens technology. It is designed to mimic the eye’s natural ability to change focus (accommodation), delivering improved vision at all distances, potentially eliminating the need for glasses or contact lenses, reducing glare and nighttime halos, and ...See details»
Abbott expected to acquire Visiogen - Ophthalmology Times
Sep 16, 2009 · Abbott has announced a definitive agreement to acquire Visiogen Inc. for $400 million in cash, providing the company with a next-generation accommodating IOL technology (Synchrony), according to a prepared statement.See details»